Xlife Sciences AG's ROE % for the quarter that ended in Dec. 2025 was -12.54%. Xlife Sciences AG's PB Ratio for the quarter that ended in Dec. 2025 was 0.50.
Xlife Sciences AG's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -25.08%.
Xlife Sciences AG ROE % Adjusted to Book Value Related Terms
Xlife Sciences AG ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG ROE % Adjusted to Book Value Chart
XSWX:XLS vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Xlife Sciences AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -25.08% mean?
Xlife Sciences AG (XSWX:XLS) has a ROE % Adjusted to Book Value of -25.08% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's ROE % Adjusted to Book Value too high?
Xlife Sciences AG's current ROE % Adjusted to Book Value is -25.08%. Overall, Xlife Sciences AG has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's ROE % Adjusted to Book Value compare to VRTX and REGN?
Xlife Sciences AG's ROE % Adjusted to Book Value of -25.08% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current ROE % Adjusted to Book Value is -25.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.30, compared to a current price of CHF20.90 — trading 186.3% above its estimated fair value. The current ROE % Adjusted to Book Value is -25.08%. Xlife Sciences AG's overall GF Score™ is 50/100 with 13 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current ROE % Adjusted to Book Value is -25.08% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF20.90 is trading 186.3% above its estimated GF Value™ of CHF7.30.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
ROE % Adjusted to Book Value: -25.08%
GF Value™: CHF7.30 vs. price of CHF20.90 (186.3% above fair value)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
50GF Score
Get the complete analysis for XSWX:XLS
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
